Cargando…

Safety and effectiveness of apixaban compared to warfarin in dialysis patients

ESSENTIALS: The safety of apixaban in patients on dialysis is currently debated. Bleeding events were retrospectively compared for dialysis patients on warfarin vs apixaban. Overall bleeding events were significantly less frequent in apixaban group compared to warfarin group. Apixaban appears to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reed, Daniel, Palkimas, Surabhi, Hockman, Rebecca, Abraham, Sumner, Le, Tri, Maitland, Hillary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055495/ https://www.ncbi.nlm.nih.gov/pubmed/30046731 http://dx.doi.org/10.1002/rth2.12083

Ejemplares similares

Profiling of warfarin pharmacokinetics‐associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics‐dosing algorithm
por: Ndadza, Arinao, et al.
Publicado: (2021)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
por: Wanat, Matthew A., et al.
Publicado: (2019)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients
por: Alotaibi, Sultan N, et al.
Publicado: (2022)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Missense VKOR mutants exhibit severe warfarin resistance but lack VKCFD via shifting to an aberrantly reduced state
por: Li, Shuang, et al.
Publicado: (2022)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels
por: Bravo Villa, Verónica, et al.
Publicado: (2021)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
por: Li, Chan, et al.
Publicado: (2019)

Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study
por: Brennan, Yvonne, et al.
Publicado: (2020)

Assessing the clinical probability of pulmonary embolism during pregnancy: The Pregnancy‐Adapted Geneva (PAG) score
por: Robert‐Ebadi, Helia, et al.
Publicado: (2021)

Risk of neonatal hypothyroidism in newborns from mothers exposed to CTPA during pregnancy: Ancillary data from a prospective outcome study
por: Righini, Marc, et al.
Publicado: (2022)

D‐dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta‐analysis
por: Bellesini, Marta, et al.
Publicado: (2021)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021)

Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study
por: Sejrup, Joakim K., et al.
Publicado: (2022)

Oxidative stress mediated platelet activation in patients with congenital analbuminemia: Effect of albumin infusion
por: Baratta, Francesco, et al.
Publicado: (2021)

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
por: Lutsey, Pamela L., et al.
Publicado: (2019)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

Apixaban/heparin/warfarin: Treatment failure: case report
Publicado: (2021)

Dual Anticoagulation With Warfarin and Apixaban: A Case Report
por: Parker, Kristen, et al.
Publicado: (2022)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Modulation of endothelial organelle size as an antithrombotic strategy
por: Ferraro, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_05nqmmprcfgui1bifbfhpp5dho